{"nctId":"NCT01498068","briefTitle":"Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C","startDateStruct":{"date":"2012-01"},"conditions":["Genotype 1 Chronic Hepatitis C"],"count":36,"armGroups":[{"label":"Treatment-naïve","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: Pegylated-interferon-alfa-2a","Drug: Ribavirin"]},{"label":"Treatment-experienced","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: Pegylated-interferon-alfa-2a","Drug: Ribavirin"]}],"interventions":[{"name":"Telaprevir","otherNames":[]},{"name":"Pegylated-interferon-alfa-2a","otherNames":[]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has genotype 1 chronic hepatitis C with HCV RNA level \\>1000 IU/mL\n* Participant is either treatment-naïve and did not receive any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C, or participant is treatment-experienced who did not achieve sustained virologic response (SVR) 24 weeks after at least 1 prior course of Peg-IFN/RBV therapy (null-responder, partial-responder or viral relapse)\n* Participant must have documentation of liver biopsy or fibroscan within 2 years before the screening visit or agree to have a biopsy or fibroscan within the screening period unless histological cirrhosis was demonstrated by a biopsy or fibroscan \\> 2 years ago prior to screening\n* A female participant of childbearing potential and a nonvasectomized male participant who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female participant ) or 7 months (male participant) after the last dose of RBV\n\nExclusion Criteria:\n\n* Prior non-responder that is classified as a viral breakthrough participant\n* Participant is infected or co-infected with HCV of another genotype than genotype 1\n* Participant has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C\n* Participant has human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection\n* Participant has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Extended Rapid Virologic Response (eRVR)","description":"A eRVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Weeks 4 and 12 of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)","description":"Changes from baseline in log10 HCV RNA levels were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.20","spread":null},{"groupId":"OG001","value":"6.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.47","spread":null},{"groupId":"OG001","value":"-5.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":null},{"groupId":"OG001","value":"-5.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.46","spread":null},{"groupId":"OG001","value":"-5.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.53","spread":null},{"groupId":"OG001","value":"-5.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":null},{"groupId":"OG001","value":"-5.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":null},{"groupId":"OG001","value":"-5.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.14","spread":null},{"groupId":"OG001","value":"-5.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Rapid Virologic Response (RVR) at Week 4","description":"A RVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Week 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48","description":"The table below shows number of participants with HCV RNA Less than 25 IU/mL, (target not detected) at Weeks 8, 12, 24, 32, 40 and 48. Only 3 treatment-naive and 14 Treatment-experienced participants were assigned to receive study treatment after Week 24. Only participants still receiving Treatment were assessed at 32, 40, and 48 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Failure","description":"Virologic failure is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels more than 1,000 IU/mL at Weeks 4, 8, 12, 24, 32, or 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Specific Category of Treatment Outcome","description":"Participants were evaluated for following 4 categories of treatment outcome;Sustained Virologic Response 12 Weeks After Last Planned Dose of Study Medication(SVR12):hepatitis C virus (HCV)ribonucleic acid (RNA)\\<25 IU/mL(target not detected)12 weeks after last planned dose of study medication;Relapse:HCV RNA =\\>25 IU/mL during follow-up period after previous HCV RNA\\<25 IU/mL at planned end of treatment(EOT)\\[Week 24 or Week 48\\] and participant did not achieve SVR12planned;On treatment virologic failure:meeting virologic stopping rule and/or having detectable HCV RNA at EOT with viral breakthrough(having a confirmed increase \\>1 log 10 in HCV RNA level from the lowest level reached or confirmed value of HCV RNA \\>100 IU/mL in participants whose HCV RNA has previously become \\<25 IU/mL during treatment).Stopping rule defined as HCV RNA value \\>1000 IU/mL at Week 4, 8 or 12 or detectable HCV RNA at Week 24, 32 or 40;Other:HCV RNA \\<25 IU/mL at actual EOT and never HCV RNA =\\>25 IU/mL thereafter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Influenza like illness","Anaemia","Pyrexia","Asthenia","Neutropenia"]}}}